Immunization, Vaccines and Biologicals

SAGE Working Group on hepatitis A vaccine (March 2010 to July 2012)

Terms of Reference

The Working Group will be asked to review the evidence with respect to the following questions/issues and to propose to SAGE recommendations, including the need to update recommendations stated in the current (2000) hepatitis A vaccine position paper:

  • Review data regarding the global prevalence and burden of disease caused by hepatitis A virus infection.
  • Review position paper recommendations regarding when countries should consider introduction of hepatitis A vaccine.
  • Review issues related to establishment of regional or global hepatitis A control goals.
  • Outline aspects of a comprehensive strategy for hepatitis A control.
  • Review issues related to hepatitis A surveillance
  • Identify additional critical issues that need to be considered in updating, referencing and providing evidence grading for the current hepatitis A vaccine position paper.

Composition

SAGE Members

  • Art Reingold, Chair. University of California, United States of America
  • Xiaofeng Liang, Chinese Center for Disease Control and Prevention, China

Experts

  • Jeffrey Mphahlele, University of Limpopo, South Africa
  • John W. Ward, Centers for Disease Control and Prevention, USA
  • Marta Vacchino, National Institute of Epidemiology, Argentina
  • Andrew Hall, London School of Hygiene and Tropical Medicine, UK
  • Daniel Shouval, Hadassah Hebrew University Hospital, Israel

WHO Secretariat

  • Steven Wiersma

DECLARATION OF INTERESTS FOR WHO EXPERTS

All members completed a declaration of interest. Only one member reported any direct interests and these interests were assessed as not relevant to the work of the Working Group.

Professor Jeffrey Mphahlele:

• His Centre receives funding from Sanofi Pasteur and Biovac SA Pty for maintenance of its website.

Last updated: 6 August 2012

Share